SI2235007T1 - Nesteroidni antagonisti mineralkortikoidnega receptorja na osnovi 6h-dibenz0 (b, e) oksepina - Google Patents
Nesteroidni antagonisti mineralkortikoidnega receptorja na osnovi 6h-dibenz0 (b, e) oksepinaInfo
- Publication number
- SI2235007T1 SI2235007T1 SI200830852T SI200830852T SI2235007T1 SI 2235007 T1 SI2235007 T1 SI 2235007T1 SI 200830852 T SI200830852 T SI 200830852T SI 200830852 T SI200830852 T SI 200830852T SI 2235007 T1 SI2235007 T1 SI 2235007T1
- Authority
- SI
- Slovenia
- Prior art keywords
- dibenz0
- oxepine
- receptor antagonists
- mineralocorticoid receptor
- derived
- Prior art date
Links
- 229940083712 aldosterone antagonist Drugs 0.000 title 1
- 239000002394 mineralocorticoid antagonist Substances 0.000 title 1
- ATYBXHSAIOKLMG-UHFFFAOYSA-N oxepin Chemical compound O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1477607P | 2007-12-19 | 2007-12-19 | |
| EP08866835A EP2235007B1 (en) | 2007-12-19 | 2008-12-09 | 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists |
| PCT/US2008/085997 WO2009085584A1 (en) | 2007-12-19 | 2008-12-09 | 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2235007T1 true SI2235007T1 (sl) | 2013-01-31 |
Family
ID=40430143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200830852T SI2235007T1 (sl) | 2007-12-19 | 2008-12-09 | Nesteroidni antagonisti mineralkortikoidnega receptorja na osnovi 6h-dibenz0 (b, e) oksepina |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US7994164B2 (OSRAM) |
| EP (2) | EP2235007B1 (OSRAM) |
| JP (1) | JP5562866B2 (OSRAM) |
| KR (1) | KR101254382B1 (OSRAM) |
| CN (1) | CN101903377B (OSRAM) |
| AR (1) | AR069554A1 (OSRAM) |
| AU (1) | AU2008343524B2 (OSRAM) |
| BR (1) | BRPI0820805A2 (OSRAM) |
| CA (1) | CA2710409C (OSRAM) |
| CL (1) | CL2008003600A1 (OSRAM) |
| CO (1) | CO6300953A2 (OSRAM) |
| DK (1) | DK2235007T3 (OSRAM) |
| DO (1) | DOP2010000185A (OSRAM) |
| EA (1) | EA017668B1 (OSRAM) |
| EC (2) | ECSP10010266A (OSRAM) |
| ES (2) | ES2459318T3 (OSRAM) |
| GT (1) | GT201000179A (OSRAM) |
| HR (1) | HRP20120916T1 (OSRAM) |
| IL (1) | IL206353A (OSRAM) |
| MA (1) | MA31910B1 (OSRAM) |
| MX (1) | MX2010006911A (OSRAM) |
| MY (1) | MY150474A (OSRAM) |
| NZ (1) | NZ586300A (OSRAM) |
| PE (1) | PE20091057A1 (OSRAM) |
| PL (1) | PL2235007T3 (OSRAM) |
| PT (1) | PT2235007E (OSRAM) |
| RS (1) | RS52594B (OSRAM) |
| SI (1) | SI2235007T1 (OSRAM) |
| TN (1) | TN2010000292A1 (OSRAM) |
| TW (1) | TWI431010B (OSRAM) |
| UA (1) | UA100131C2 (OSRAM) |
| WO (1) | WO2009085584A1 (OSRAM) |
| ZA (1) | ZA201004257B (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010535156A (ja) | 2007-08-03 | 2010-11-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ウイルスポリメラーゼ阻害剤 |
| MX2010006313A (es) | 2007-12-19 | 2010-06-25 | Boehringer Ingelheim Int | Inhibidores de la polimerasa virica. |
| BRPI1009257A2 (pt) * | 2009-03-12 | 2016-03-08 | Lilly Co Eli | antagonista receptor de mineralocorticoide e métodos de uso. |
| ES2641144T3 (es) | 2010-05-10 | 2017-11-07 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina |
| US9241944B2 (en) | 2010-06-16 | 2016-01-26 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Methods and compositions for stimulating reepithelialisation during wound healing |
| CN102060670A (zh) * | 2011-01-04 | 2011-05-18 | 常州大学 | 一种2-溴-6-氟苯甲醇的制备方法 |
| JP6263606B2 (ja) | 2013-05-02 | 2018-01-17 | ファイザー・インク | Ｐｄｅ１０阻害剤としてのイミダゾ−トリアジン誘導体 |
| AR099416A1 (es) | 2014-02-28 | 2016-07-20 | Lilly Co Eli | Terapia combinada para la hipertensión resistente |
| ES2707726T3 (es) | 2014-06-30 | 2019-04-04 | Astrazeneca Ab | Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides |
| US20170246166A1 (en) * | 2014-11-21 | 2017-08-31 | Eli Lilly And Company | 1,2-benzothiazole compounds for the treatment of kidney disorders |
| JP6835836B2 (ja) | 2015-10-13 | 2021-02-24 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 脈絡膜血管新生の処置のための方法及び医薬組成物 |
| US20190262363A1 (en) | 2016-07-26 | 2019-08-29 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis |
| CU24569B1 (es) * | 2016-09-24 | 2022-01-13 | Kbp Biosciences Co Ltd | Composición farmacéutica como antagonista del receptor de mineralocorticoides |
| US20230151425A1 (en) | 2020-03-11 | 2023-05-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy |
| WO2023031277A1 (en) | 2021-08-31 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of ocular rosacea |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4072756A (en) * | 1973-05-17 | 1978-02-07 | Sandoz Ltd. | Tricyclo piperidino ketones and soporific compositions thereof |
| SE426341C (sv) * | 1980-02-14 | 1985-09-23 | Fagersta Ab | Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser |
| DE3730258A1 (de) * | 1986-09-10 | 1988-04-07 | Canon Kk | Elektrophotographisches lichtempfindliches aufzeichnungsmaterial, 5h-dibenzo(a,d)cycloheptanylidenderivat, 5h-dibenzo(a,d)cycloheptenylidenderivat und verfahren zu ihrer herstellung |
| US4999363A (en) * | 1988-06-09 | 1991-03-12 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds |
| GB8914061D0 (en) * | 1989-06-19 | 1989-08-09 | Wellcome Found | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
| US5378701A (en) * | 1991-12-27 | 1995-01-03 | Kyowa Hakko Kogyo | Tricyclic compounds |
| ZA9811898B (en) | 1997-12-29 | 2000-06-28 | Ortho Mcneil Pharm Inc | Anti-Inflammatory Compounds. |
| CA2361734A1 (en) | 1999-01-26 | 2000-10-12 | Andre Rosowsky | Pharmaceutically active compounds and methods of use thereof |
| CN1911930A (zh) * | 2001-11-21 | 2007-02-14 | 千禧药品公司 | 趋化因子受体拮抗剂及其方法和用途 |
| TW200400816A (en) * | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
| AU2004312293A1 (en) | 2003-12-19 | 2005-07-21 | Eli Lilly And Company | Tricyclic steroid hormone nuclear receptor modulators |
| WO2005066153A1 (en) | 2003-12-19 | 2005-07-21 | Eli Lilly And Company | Tricyclic steroid hormone nuclear receptor modulators |
| TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
| WO2006015259A2 (en) | 2004-07-28 | 2006-02-09 | Irm Llc | Compounds and compositions as modulators of steroid hormone nuclear receptors |
| AU2005304560C1 (en) | 2004-11-10 | 2013-05-09 | Incyte Holdings Corporation | Lactam compounds and their use as pharmaceuticals |
| GEP20115239B (en) | 2006-10-31 | 2011-06-10 | Pfizer Prod Inc | Pyrazoline compounds as mineralocorticoid receptor antagonists |
| WO2008119918A1 (en) | 2007-03-29 | 2008-10-09 | N.V. Organon | Mineralocorticoid receptor antagonists |
| PE20091339A1 (es) | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
| GB0725102D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| US20100292233A1 (en) | 2008-01-25 | 2010-11-18 | Arena Pharmaceuticals, Inc. | Dihydro-1h-pyrrolo[1,2-a]indol-1-yl carboxylic acid derivatives which act as s1p1 agonists |
| BRPI1009257A2 (pt) | 2009-03-12 | 2016-03-08 | Lilly Co Eli | antagonista receptor de mineralocorticoide e métodos de uso. |
-
2008
- 2008-12-02 TW TW097146779A patent/TWI431010B/zh not_active IP Right Cessation
- 2008-12-02 PE PE2008002008A patent/PE20091057A1/es not_active Application Discontinuation
- 2008-12-03 CL CL2008003600A patent/CL2008003600A1/es unknown
- 2008-12-03 AR ARP080105263A patent/AR069554A1/es unknown
- 2008-12-09 DK DK08866835.5T patent/DK2235007T3/da active
- 2008-12-09 MY MYPI20102867 patent/MY150474A/en unknown
- 2008-12-09 BR BRPI0820805-0A patent/BRPI0820805A2/pt not_active IP Right Cessation
- 2008-12-09 PL PL08866835T patent/PL2235007T3/pl unknown
- 2008-12-09 ES ES12185389.9T patent/ES2459318T3/es active Active
- 2008-12-09 CN CN200880121527.2A patent/CN101903377B/zh not_active Expired - Fee Related
- 2008-12-09 PT PT88668355T patent/PT2235007E/pt unknown
- 2008-12-09 JP JP2010539618A patent/JP5562866B2/ja not_active Expired - Fee Related
- 2008-12-09 US US12/330,539 patent/US7994164B2/en not_active Expired - Fee Related
- 2008-12-09 WO PCT/US2008/085997 patent/WO2009085584A1/en not_active Ceased
- 2008-12-09 SI SI200830852T patent/SI2235007T1/sl unknown
- 2008-12-09 ES ES08866835T patent/ES2396605T3/es active Active
- 2008-12-09 KR KR1020107013601A patent/KR101254382B1/ko not_active Expired - Fee Related
- 2008-12-09 EP EP08866835A patent/EP2235007B1/en active Active
- 2008-12-09 MX MX2010006911A patent/MX2010006911A/es active IP Right Grant
- 2008-12-09 RS RS20120541A patent/RS52594B/sr unknown
- 2008-12-09 UA UAA201007627A patent/UA100131C2/uk unknown
- 2008-12-09 NZ NZ586300A patent/NZ586300A/en not_active IP Right Cessation
- 2008-12-09 CA CA2710409A patent/CA2710409C/en not_active Expired - Fee Related
- 2008-12-09 HR HRP20120916AT patent/HRP20120916T1/hr unknown
- 2008-12-09 AU AU2008343524A patent/AU2008343524B2/en not_active Ceased
- 2008-12-09 EA EA201070762A patent/EA017668B1/ru not_active IP Right Cessation
- 2008-12-09 EP EP12185389.9A patent/EP2537845B1/en active Active
-
2010
- 2010-06-14 IL IL206353A patent/IL206353A/en not_active IP Right Cessation
- 2010-06-14 MA MA32909A patent/MA31910B1/fr unknown
- 2010-06-15 ZA ZA2010/04257A patent/ZA201004257B/en unknown
- 2010-06-16 CO CO10072532A patent/CO6300953A2/es not_active Application Discontinuation
- 2010-06-17 GT GT201000179A patent/GT201000179A/es unknown
- 2010-06-17 DO DO2010000185A patent/DOP2010000185A/es unknown
- 2010-06-17 EC EC2010010266A patent/ECSP10010266A/es unknown
- 2010-06-18 TN TN2010000292A patent/TN2010000292A1/fr unknown
-
2012
- 2012-07-17 EC ECSP12012048 patent/ECSP12012048A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2235007T1 (sl) | Nesteroidni antagonisti mineralkortikoidnega receptorja na osnovi 6h-dibenz0 (b, e) oksepina | |
| EP2184278A4 (en) | P2X4 RECEIVER ANTAGONIST | |
| EP2058304A4 (en) | P2X4 RECEPTOR ANTAGONIST | |
| PT1981902E (pt) | Antagonistas dos recetores nogo | |
| AP2011005685A0 (en) | Azaindazole compounds as CCRI receptor. | |
| AP2010005267A0 (en) | Novel glucocorticoid receptor agonists | |
| IL184816A0 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
| AP2011005988A0 (en) | Compounds which selectively modulate the CB2 receptor. | |
| IL198241A0 (en) | Pyrazoline compounds as mineralocorticoid receptor antagonists | |
| ZA200906812B (en) | Crig antagonists | |
| GB0717233D0 (en) | Traffic monitoring | |
| SMT201800211T1 (it) | Antagonisti del recettore clever-1 per bloccare i macrofagi immuno-inibitori di tipo 2 | |
| IL198542A0 (en) | 2-aminoquinolines as 5-ht(5a)receptor antagonists | |
| EP2153736A4 (en) | NEW LEUKOTRIEN RECEPTOR ANTAGONIST | |
| IL218525A0 (en) | 1,2-dihydro-2-oxoquinoline compounds as 5-ht4 receptor ligands | |
| GB0820231D0 (en) | Airbagmodul, airbagmodulanordung und befestigungsverfahren | |
| EP2387058A4 (en) | THERMAL SENSITIVE TEMPERATURE FUSE IN TABLET FORM | |
| IL207700A0 (en) | 3-aminoalkyl-1,4-diazepan-2-one melanocortin -5 receptor antagonists | |
| IL207438A0 (en) | 2-aminoquinolines as 5-ht5a receptor antagonists | |
| IL211803A0 (en) | Quinazoline derivatives as nk3 receptor antagonists | |
| PL117149U1 (pl) | Wkładka bezpiecznikowa | |
| GB0704284D0 (en) | Es,e-o hi-grip peel-n-seal | |
| GB0701632D0 (en) | MET receptor antagonists | |
| ZA201000956B (en) | TSH receptor antagonizing tetrahydroquinoline compounds | |
| HK1155164A (en) | Sphingosine-1-phosphate receptor antagonists |